China's medical products administrator approved Nanjing King-Friend Biochemical Pharmaceutical's (SHA:603707) drug registration for its fulvestrant injection for breast cancer, according to a Tuesday filing with the Shanghai Stock Exchange.
The drug is indicated for post-menopausal estrogen-receptor-positive locally advanced or metastatic breast cancer that relapses following or during anti-estrogen adjuvant therapy, the filing said.
The injection is used simultaneously with abemaciclib for hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer, among other types, the filing said.
Shares closed 2% higher during Tuesday's afternoon trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。